Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDPApproval based on ADHERE clinical trial, the ...

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...

European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...

The Australian swimming legend and triple Olympian opens up about finding hope and courage in the face of a chronic health ...

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...

Michael Klim has revealed details about his five-year battle with a rare autoimmune disorder which left him unable to walk - ...

Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company announced that the European Commission ...

The FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in rare autoimmune disease chronic inflammatory demyelinating polyneuropathy (CIDP).

After retiring from elite sport, Michael Klim’s toughest test came with a CIDP diagnosis—an experience that he says has ...